 Marrone Bio Innovations Inc NASDAQ:MBII reported a 31 year-over-year surge in its fiscal 2020 revenue to 38.4 million, driven largely by the companys expanded product line and international footprint. Marrone also said its net loss and adjusted EBITDA for the year improved by 46 and 31, respectively, achieving gross margins of 59.6 as a result of an improved product mix. 